癌症登记软件市场：到 2028 年的预测——按类型、数据库类型、功能、部署模型、最终用户和地区进行的全球分析

根据 Stratistics MRC 的数据，2022 年全球癌症登记软件市场规模将达到 597.2 亿美元，预计到 2028 年将达到 1123.2 亿美元，根据预测期预计将以期间复合年增长率为 11.1%

癌症登记软件可自动收集国家和州登记处的数据，并有助于跟踪不同治疗方案的有效性。 此外，国家登记处收集的数据有助于我们更好地了解和治疗疾病。 收集的信息对于识别风险因素很重要，例如环境风险，如烟草使用、阳光照射、化学品和辐射暴露。 还需要这些数据来遵循筛查和治疗方案，并确定可以在哪些方面进行改进。 此外，登记数据有助于研究机构衡量癌症管理、治疗和预防计划的有效性。

根据 Proteus Breach 的数据，2019 年医疗保健行业有 4140 万条患者记录遭到破坏，数量惊人。

市场动态。

驱动程序

癌症患者的患病率增加

乳腺癌、宫颈癌和前列腺癌是美国和欧洲人群中最常见的癌症。 为了解趋势并确定原因，医学研究人员需要有关癌症的最新数据，包括诊断出患有癌症的人口、接受治疗的患者人数和死亡率。 医疗保健从业者需要癌症发病率统计数据来帮助确定需要购买多少设备和药物来进行治疗和提高认识。 在预测期内，越来越多地利用癌症登记处收集、存储和管理数据将对市场焦点产生积极影响。

约束

数据隐私和安□□全

由于该系统收集高度个人化的数据，数据隐私和安□□全问题将成为预测期内癌症登记软件市场的主要障碍。 癌症登记处收集患者人口统计数据、肿瘤特征、治疗和疾病结果等信息。 政府机构专注于执行新的法规和法律，以确保信息的安全管理。 《健康保险流通与责任法案》和美国卫生与公众服务部 (HHS) 还列出了各种有关消费者健康数据保护和隐私的联邦法规。

机会

肿瘤学临床研究的增加

製药公司和研究机构正在进行临床试验，以开发新的癌症治疗技术。 在临床试验和研究期间对註册数据进行深入分析有助于确定癌症原因和治疗方法，以便更好地进行监测。 癌症登记被研究机构和製药公司用作 III 期和 IV 期临床研究的后续材料。 开发复杂的癌症登记软件有助于提高公共和私人癌症登记处的数据质量。 这将有助于未来几年市场的扩张。

威胁

缺乏互操作性/集成

EHR 系统与独立癌症登记软件之间缺乏连通性阻碍了新替代品的开发。 预计此类数据交换问题将需要人工干预，以在不同 EHR 系统之间导入或导出患者记录，直到建立跨国家和地区的通用健康信息交换系统。 因此，不完全兼容的 EHR 的广泛采用给癌症患者登记软件供应商带来了重大问题。

COVID-19 的影响

由于 COVID-19 大流行，癌症诊断在大流行期间显着下降，化疗、手术和其他辅助癌症治疗也是如此。 医生要求我在内窥镜切除术后、手术切除术后和息肉切除术后推迟癌症治疗。 它还建议推迟对感染风险高的癌症患者进行筛查，从而减少治疗工作。 政府承诺未来资助註册业务作为疾病控制资产，并转向电子报告系统，可以确保癌症监测领域的可持续性。

预计在预测期内集成软件部分将成为最大的部分

由于对软件与区域肿瘤学网络的集成需求不断增加，预计集成软件部分将实现利润丰厚的增长。 这可能有助于跟踪受影响区域的地理位置并评估治疗干预措施。 它还有助于收集有关疾病负担的数据和治疗方案的成功。 此外，需要与筛查檔案合作，以识别筛查检测到的癌症并改进评估程序。 这些因素预计将在未来几年推动这一领域的扩张。

预计商业数据库领域在预测期内的复合年增长率最高

由于与公共数据库相比，商业数据库具有更高的数据安全性优势，因此预计在预测期内将以最快的复合年增长率增长。 商业数据库符合大多数联邦政府的要求和规范。 此外，数据结构化且易于跟踪。 商业技术使疾病控制和预防中心 (CDC) 等政府研究机构与中央癌症登记处之间的数据传输成为可能。

市场份额最大的地区

由于基础设施发达，预计北美在预测期内将占据最大的市场份额。 该地区先进的基础设施和不断增加的创新研发投资是推动癌症登记软件市场增长的关键因素。 根据美国国立卫生研究院 (NIH) 的数据，癌症是美国第二大死因。 在该地区，由于吸烟和缺乏运动等因素导致的癌症发病率正在增加，这推动了市场的扩张。

复合年增长率最高的地区。

由于政府举措的增加，预计亚太地区在预测期内的复合年增长率最高。 在日本，厚生劳动省正在启动一个项目，以加强该国的医疗保健基础设施。 在中国，第十二个五年计划宣布建立区域医疗保健信息网络 (RHIN)。 此外，製药业务向中国和印度等低成本製造国家的转移正在推动亚太行业向前发展。

取得了重大进展。

2022 年 3 月，Elekta 宣布国家卫生服务供应链 (NHSSC) 将订购 Elekta ProKnow 软件解决方案的多个许可，以在安全且高度可扩展的平台上集中管理和分析放射治疗数据。NHS England (NHSE) 辐射肿瘤科设施现已开放。

2018 年 11 月，Onco 升级了 OncoLog 版本 4.4.0，以包含 NAACCR、AJCC、CoC 和 SEER 规定的最新要求。

我们的报告提供了什么

• 区域和国家级细分市场的市场份额评估
• 向新进入者提出战略建议
• 2020、2021、2022、2025 和 2028 年的综合市场数据
• 市场驱动因素（市场趋势、制约因素、机遇、威胁、挑战、投资机会、建议等）
• 根据市场预测在关键业务领域提出战略建议
• 竞争格局和趋势
• 公司简介，包括详细的战略、财务状况和近期发展
• 供应链趋势反映了最新的技术进步。

提供免费定制

购买此报告的客户将免费获得以下定制之一。

• 公司简介
  • 对其他市场参与者（最多 3 个）进行全面分析
  • 关键参与者的 SWOT 分析（最多 3 名参与者）
• 区域细分
  • 根据客户要求提供主要国家/地区的市场估算、预测和復合年增长率（注意：不包括可行性检查。）
• 竞争基准
  • 根据产品组合、地域分布和战略联盟对主要参与者进行基准测试

内容

第 1 章执行摘要

第二章前言

• 概览
• 利益相关者
• 调查范围
• 调查方法
  • 数据挖掘
  • 数据分析
  • 数据验证
  • 研究方法
• 调查来源
  • 主要研究信息来源
  • 二手研究资源
  • 假设

第三章市场趋势分析

• 司机
• 约束因素
• 机会
• 威胁
• 最终用户分析
• 新兴市场
• COVID-19 的影响

第4章波特五力分析

• 供应商的议价能力
• 买家的议价能力
• 替代品的威胁
• 新进入者的威胁
• 竞争公司之间的敌对关係

第 5 章全球癌症登记软件市场：按类型

• 独立软件
• 集成软件

第 6 章全球癌症登记软件市场：按数据库类型

• 公共数据库
• 商业数据库

第 7 章全球癌症登记软件市场：按功能分类

• 产品性能评估
• 符合州和联邦法规的癌症报告
• 医学研究和临床研究
• 患者护理管理

第 8 章全球癌症登记软件市场：按部署模型

• 基于云
• 本地

第 9 章全球癌症登记软件市场：按最终用户分类

• 研究中心
• 医院和医疗机构
• 个人付款人
• 製药、生物技术和医疗设备公司
• 政府机构和第三方管理员

第 10 章全球癌症登记软件市场：按地区

• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 意大利
  • 法国
  • 西班牙
  • 其他欧洲
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳大利亚
  • 新西兰
  • 韩国
  • 其他亚太地区
• 南美洲
  • 阿根廷
  • 巴西
  • 智利
  • 其他南美洲
• 中东和非洲
  • 沙特阿拉伯
  • 阿拉伯联合酋长国
  • 卡塔尔
  • 南非
  • 其他中东地区

第11章主要发展

• 合同、伙伴关係、协作和合资企业
• 收购与合併
• 新产品发布
• 业务扩展
• 其他关键策略

第12章公司简介

• IBM Corporation
• McKesson Corporation
• Himagine Solutions Inc.
• CONDUENT Inc.
• C/Net Solutions
• Elekta AB
• Rocky Mountain Cancer Data Systems
• Ordinal Data Inc.
• Electronic Registry Systems Inc.
• Onco Inc.
• F. Hoffmann-La Roche Ltd
• Netdox Health Pvt. Ltd.
• Centers for Disease Control and Prevention

According to Stratistics MRC, the Global Cancer Registry Software Market is accounted for $59.72 billion in 2022 and is expected to reach $112.32 billion by 2028 growing at a CAGR of 11.1% during the forecast period. The cancer registry software automates data collecting for national and state registries, which aids in tracking the effectiveness of various treatment regimens. Furthermore, the data collected by the state registries aid in better understanding and treatment of the condition. The information gathered is critical in identifying risk factors such as tobacco usage, sun exposure, or environmental risks such as chemical and radiation exposure. This data is also required for determining where screening and treatment options should be tracked and improved. Furthermore, registry data can help research institutes measure the effectiveness of cancer management, treatment, and preventive programmes.

According to Proteus Breach, healthcare sector saw a massive 41.4 million patient records breached in 2019.

Market Dynamics:

Driver:

Growing prevalence of cancer cases

Breast, cervical, and prostate cancers are extremely common in the populations of the United States and Europe. To track trends and examine the possible causes of cancer, medical researchers require up-to-date data on cancer, such as the population diagnosed with cancer, patients undergoing treatment, and mortality rate. Healthcare professionals require cancer incidence statistics in order to make judgements about the amount of equipment and drugs to purchase for treatment and awareness. The increased usage of cancer registry systems for data collecting, storage, and management would have a favourable impact on the market focus during the projection period.

Restraint:

Data privacy and security

Data privacy and security issues, as the system collects highly personal data, will be a major barrier for the cancer registry software market over the projection period. Cancer registries collect information such as patient demographics, tumour features, treatment, and disease outcome. Government agencies are concentrating on the implementation of new regulations and laws to ensure the safe management of information. Various federal regulations are also listed in the Health Insurance Portability and Accountability Act and the US Department of Health and Human Services (HHS) for the protection and privacy of consumer health data.

Opportunity:

Increasing clinical research for oncology

Clinical trials are being conducted by pharmaceutical companies and research organisations in order to develop novel cancer treatment techniques. Clinical trials and in-depth analyses of registry data during clinical research aid in the identification of proper monitoring of cancer causes and therapies. Cancer registries are used by research institutes and pharmaceutical corporations as a follow-up source during phase III and phase IV clinical studies. The development of sophisticated cancer registry software assists public and private cancer registry organisations in improving data quality. This will help the market's expansion in the coming years.

Threat:

Lack of interoperability and integration

The lack of connectivity between EHR systems and independent cancer patient registration software has impeded the development of novel alternatives. These types of data exchange problems are expected to continue to necessitate manual methods for importing or exporting patient records between different EHR systems until a universal health information exchange system is built throughout a country/region. As a result, broad adoption of EHRs that are not fully compatible poses a significant problem for cancer patient registry software suppliers.

COVID-19 Impact

Because of the COVID-19 pandemic, cancer diagnoses declined considerably during the pandemic, as did chemotherapy, surgery, and other supporting cancer treatments. Doctors were urged to postpone post-endoscopic resection, surgical resection of cancer, and post-polypectomy cancer. They also recommended that screening for high-risk cancer patients be postponed due to the risk of infection, which resulted in a reduction in treatment operations. A government commitment to fund future registry operations as a disease control asset, along with a shift towards electronic reporting systems, would help to secure the global sustainability of cancer surveillance.

The integrated software segment is expected to be the largest during the forecast period

The integrated software segment is estimated to have a lucrative growth, due to the increasing demand for integrating software with a regional oncology network. This will aid in tracking affected geographic locations and evaluating the treatment intervention. It will also contribute in the collection of data on illness burden and the success of treatment programmes. Furthermore, linkage with screening archives is required to identify screen-detected cancers and improve evaluation procedures. These factors are projected to drive the expansion of this segment in the next years.

The commercial database segment is expected to have the highest CAGR during the forecast period

The commercial database segment is anticipated to witness the fastest CAGR growth during the forecast period, due to its advantage of data safety as compared to the public database. The commercial database complies with most federal requirements and codes. The data is also well-structured and simple to follow. Commercial technologies enable data transmission among government research agencies such as the Centers for Disease Control and Prevention (CDC) and central cancer registries.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the presence of developed infrastructure. The region's advanced infrastructure and increased investment in research & development for innovation are important factors driving the growth of the cancer registry software market. Cancer is the second highest cause of mortality in the United States, according to the National Institutes of Health (NIH). The rising incidence of cancer in this region, owing to cigarette use and a lack of physical exercise, among other factors, is fuelling market expansion.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to increasing government initiatives being undertaken in this region. In Japan, the Ministry of Health, Labour, and Welfare has launched projects to strengthen the country's healthcare infrastructure. China has also unveiled its 12th Five-Year Plan to improve the country's Regional Healthcare Information Networks (RHINs). Furthermore, the movement of pharmaceutical businesses to low-cost manufacturing countries such as China and India is moving the Asia Pacific industry forward.

Key players in the market

Some of the key players profiled in the Cancer Registry Software Market include: IBM Corporation, McKesson Corporation, Himagine Solutions Inc., CONDUENT Inc., C/Net Solutions, Elekta AB, Rocky Mountain Cancer Data Systems, Ordinal Data Inc., Electronic Registry Systems Inc., Onco Inc., F. Hoffmann-La Roche Ltd, Netdox Health Pvt. Ltd. and Centers for Disease Control and Prevention

Key Developments:

In March 2022, Elekta stated that National Health Service Supply Chain (NHSSC) had ordered multiple licenses for Elekta's ProKnow software solution, which centralizes and analyzes radiotherapy data in a secure, scalable platform, accessible to the NHS England's (NHSE's) radiation oncology facilities throughout the country.

In November 2018, Onco upgraded the OncoLog Version 4.4.0 to include the newest requirements mandated by NAACCR, AJCC, CoC and SEER.

Types Covered:

• Standalone Software
• Integrated Software

Database Types Covered:

• Public Database
• Commercial Database

Functionalities Covered:

• Product Outcome Evaluation
• Cancer Reporting to Meet State and Federal Regulations
• Medical Research & Clinical Studies
• Patient Care Management

Deployment Models Covered:

• Cloud-based
• On-premise

End Users Covered:

• Research Centre
• Hospitals & Medical Practices
• Private Payers
• Pharmaceutical, Biotechnology, and Medical Device Companies
• Government Organizations & Third-Party Administrators

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Cancer Registry Software Market, By Type

• 5.1 Introduction
• 5.2 Standalone Software
• 5.3 Integrated Software

6 Global Cancer Registry Software Market, By Database Type

• 6.1 Introduction
• 6.2 Public Database
• 6.3 Commercial Database

7 Global Cancer Registry Software Market, By Functionality

• 7.1 Introduction
• 7.2 Product Outcome Evaluation
• 7.3 Cancer Reporting to Meet State and Federal Regulations
• 7.4 Medical Research & Clinical Studies
• 7.5 Patient Care Management

8 Global Cancer Registry Software Market, By Deployment Model

• 8.1 Introduction
• 8.2 Cloud-based
• 8.3 On-premise

9 Global Cancer Registry Software Market, By End User

• 9.1 Introduction
• 9.2 Research Centre
• 9.3 Hospitals & Medical Practices
• 9.4 Private Payers
• 9.5 Pharmaceutical, Biotechnology, and Medical Device Companies
• 9.6 Government Organizations & Third-Party Administrators

10 Global Cancer Registry Software Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 IBM Corporation
• 12.2 McKesson Corporation
• 12.3 Himagine Solutions Inc.
• 12.4 CONDUENT Inc.
• 12.5 C/Net Solutions
• 12.6 Elekta AB
• 12.7 Rocky Mountain Cancer Data Systems
• 12.8 Ordinal Data Inc.
• 12.9 Electronic Registry Systems Inc.
• 12.10 Onco Inc.
• 12.11 F. Hoffmann-La Roche Ltd
• 12.12 Netdox Health Pvt. Ltd.
• 12.13 Centers for Disease Control and Prevention

List of Tables

• Table 1 Global Cancer Registry Software Market Outlook, By Region (2020-2028) ($MN)
• Table 2 Global Cancer Registry Software Market Outlook, By Type (2020-2028) ($MN)
• Table 3 Global Cancer Registry Software Market Outlook, By Standalone Software (2020-2028) ($MN)
• Table 4 Global Cancer Registry Software Market Outlook, By Integrated Software (2020-2028) ($MN)
• Table 5 Global Cancer Registry Software Market Outlook, By Database Type (2020-2028) ($MN)
• Table 6 Global Cancer Registry Software Market Outlook, By Public Database (2020-2028) ($MN)
• Table 7 Global Cancer Registry Software Market Outlook, By Commercial Database (2020-2028) ($MN)
• Table 8 Global Cancer Registry Software Market Outlook, By Functionality (2020-2028) ($MN)
• Table 9 Global Cancer Registry Software Market Outlook, By Product Outcome Evaluation (2020-2028) ($MN)
• Table 10 Global Cancer Registry Software Market Outlook, By Cancer Reporting to Meet State and Federal Regulations (2020-2028) ($MN)
• Table 11 Global Cancer Registry Software Market Outlook, By Medical Research & Clinical Studies (2020-2028) ($MN)
• Table 12 Global Cancer Registry Software Market Outlook, By Patient Care Management (2020-2028) ($MN)
• Table 13 Global Cancer Registry Software Market Outlook, By Deployment Model (2020-2028) ($MN)
• Table 14 Global Cancer Registry Software Market Outlook, By Cloud-based (2020-2028) ($MN)
• Table 15 Global Cancer Registry Software Market Outlook, By On-premise (2020-2028) ($MN)
• Table 16 Global Cancer Registry Software Market Outlook, By End User (2020-2028) ($MN)
• Table 17 Global Cancer Registry Software Market Outlook, By Research Centre (2020-2028) ($MN)
• Table 18 Global Cancer Registry Software Market Outlook, By Hospitals & Medical Practices (2020-2028) ($MN)
• Table 19 Global Cancer Registry Software Market Outlook, By Private Payers (2020-2028) ($MN)
• Table 20 Global Cancer Registry Software Market Outlook, By Pharmaceutical, Biotechnology, and Medical Device Companies (2020-2028) ($MN)
• Table 21 Global Cancer Registry Software Market Outlook, By Government Organizations & Third-Party Administrators (2020-2028) ($MN)
• Table 22 North America Cancer Registry Software Market Outlook, By Country (2020-2028) ($MN)
• Table 23 North America Cancer Registry Software Market Outlook, By Type (2020-2028) ($MN)
• Table 24 North America Cancer Registry Software Market Outlook, By Standalone Software (2020-2028) ($MN)
• Table 25 North America Cancer Registry Software Market Outlook, By Integrated Software (2020-2028) ($MN)
• Table 26 North America Cancer Registry Software Market Outlook, By Database Type (2020-2028) ($MN)
• Table 27 North America Cancer Registry Software Market Outlook, By Public Database (2020-2028) ($MN)
• Table 28 North America Cancer Registry Software Market Outlook, By Commercial Database (2020-2028) ($MN)
• Table 29 North America Cancer Registry Software Market Outlook, By Functionality (2020-2028) ($MN)
• Table 30 North America Cancer Registry Software Market Outlook, By Product Outcome Evaluation (2020-2028) ($MN)
• Table 31 North America Cancer Registry Software Market Outlook, By Cancer Reporting to Meet State and Federal Regulations (2020-2028) ($MN)
• Table 32 North America Cancer Registry Software Market Outlook, By Medical Research & Clinical Studies (2020-2028) ($MN)
• Table 33 North America Cancer Registry Software Market Outlook, By Patient Care Management (2020-2028) ($MN)
• Table 34 North America Cancer Registry Software Market Outlook, By Deployment Model (2020-2028) ($MN)
• Table 35 North America Cancer Registry Software Market Outlook, By Cloud-based (2020-2028) ($MN)
• Table 36 North America Cancer Registry Software Market Outlook, By On-premise (2020-2028) ($MN)
• Table 37 North America Cancer Registry Software Market Outlook, By End User (2020-2028) ($MN)
• Table 38 North America Cancer Registry Software Market Outlook, By Research Centre (2020-2028) ($MN)
• Table 39 North America Cancer Registry Software Market Outlook, By Hospitals & Medical Practices (2020-2028) ($MN)
• Table 40 North America Cancer Registry Software Market Outlook, By Private Payers (2020-2028) ($MN)
• Table 41 North America Cancer Registry Software Market Outlook, By Pharmaceutical, Biotechnology, and Medical Device Companies (2020-2028) ($MN)
• Table 42 North America Cancer Registry Software Market Outlook, By Government Organizations & Third-Party Administrators (2020-2028) ($MN)
• Table 43 Europe Cancer Registry Software Market Outlook, By Country (2020-2028) ($MN)
• Table 44 Europe Cancer Registry Software Market Outlook, By Type (2020-2028) ($MN)
• Table 45 Europe Cancer Registry Software Market Outlook, By Standalone Software (2020-2028) ($MN)
• Table 46 Europe Cancer Registry Software Market Outlook, By Integrated Software (2020-2028) ($MN)
• Table 47 Europe Cancer Registry Software Market Outlook, By Database Type (2020-2028) ($MN)
• Table 48 Europe Cancer Registry Software Market Outlook, By Public Database (2020-2028) ($MN)
• Table 49 Europe Cancer Registry Software Market Outlook, By Commercial Database (2020-2028) ($MN)
• Table 50 Europe Cancer Registry Software Market Outlook, By Functionality (2020-2028) ($MN)
• Table 51 Europe Cancer Registry Software Market Outlook, By Product Outcome Evaluation (2020-2028) ($MN)
• Table 52 Europe Cancer Registry Software Market Outlook, By Cancer Reporting to Meet State and Federal Regulations (2020-2028) ($MN)
• Table 53 Europe Cancer Registry Software Market Outlook, By Medical Research & Clinical Studies (2020-2028) ($MN)
• Table 54 Europe Cancer Registry Software Market Outlook, By Patient Care Management (2020-2028) ($MN)
• Table 55 Europe Cancer Registry Software Market Outlook, By Deployment Model (2020-2028) ($MN)
• Table 56 Europe Cancer Registry Software Market Outlook, By Cloud-based (2020-2028) ($MN)
• Table 57 Europe Cancer Registry Software Market Outlook, By On-premise (2020-2028) ($MN)
• Table 58 Europe Cancer Registry Software Market Outlook, By End User (2020-2028) ($MN)
• Table 59 Europe Cancer Registry Software Market Outlook, By Research Centre (2020-2028) ($MN)
• Table 60 Europe Cancer Registry Software Market Outlook, By Hospitals & Medical Practices (2020-2028) ($MN)
• Table 61 Europe Cancer Registry Software Market Outlook, By Private Payers (2020-2028) ($MN)
• Table 62 Europe Cancer Registry Software Market Outlook, By Pharmaceutical, Biotechnology, and Medical Device Companies (2020-2028) ($MN)
• Table 63 Europe Cancer Registry Software Market Outlook, By Government Organizations & Third-Party Administrators (2020-2028) ($MN)
• Table 64 Asia Pacific Cancer Registry Software Market Outlook, By Country (2020-2028) ($MN)
• Table 65 Asia Pacific Cancer Registry Software Market Outlook, By Type (2020-2028) ($MN)
• Table 66 Asia Pacific Cancer Registry Software Market Outlook, By Standalone Software (2020-2028) ($MN)
• Table 67 Asia Pacific Cancer Registry Software Market Outlook, By Integrated Software (2020-2028) ($MN)
• Table 68 Asia Pacific Cancer Registry Software Market Outlook, By Database Type (2020-2028) ($MN)
• Table 69 Asia Pacific Cancer Registry Software Market Outlook, By Public Database (2020-2028) ($MN)
• Table 70 Asia Pacific Cancer Registry Software Market Outlook, By Commercial Database (2020-2028) ($MN)
• Table 71 Asia Pacific Cancer Registry Software Market Outlook, By Functionality (2020-2028) ($MN)
• Table 72 Asia Pacific Cancer Registry Software Market Outlook, By Product Outcome Evaluation (2020-2028) ($MN)
• Table 73 Asia Pacific Cancer Registry Software Market Outlook, By Cancer Reporting to Meet State and Federal Regulations (2020-2028) ($MN)
• Table 74 Asia Pacific Cancer Registry Software Market Outlook, By Medical Research & Clinical Studies (2020-2028) ($MN)
• Table 75 Asia Pacific Cancer Registry Software Market Outlook, By Patient Care Management (2020-2028) ($MN)
• Table 76 Asia Pacific Cancer Registry Software Market Outlook, By Deployment Model (2020-2028) ($MN)
• Table 77 Asia Pacific Cancer Registry Software Market Outlook, By Cloud-based (2020-2028) ($MN)
• Table 78 Asia Pacific Cancer Registry Software Market Outlook, By On-premise (2020-2028) ($MN)
• Table 79 Asia Pacific Cancer Registry Software Market Outlook, By End User (2020-2028) ($MN)
• Table 80 Asia Pacific Cancer Registry Software Market Outlook, By Research Centre (2020-2028) ($MN)
• Table 81 Asia Pacific Cancer Registry Software Market Outlook, By Hospitals & Medical Practices (2020-2028) ($MN)
• Table 82 Asia Pacific Cancer Registry Software Market Outlook, By Private Payers (2020-2028) ($MN)
• Table 83 Asia Pacific Cancer Registry Software Market Outlook, By Pharmaceutical, Biotechnology, and Medical Device Companies (2020-2028) ($MN)
• Table 84 Asia Pacific Cancer Registry Software Market Outlook, By Government Organizations & Third-Party Administrators (2020-2028) ($MN)
• Table 85 South America Cancer Registry Software Market Outlook, By Country (2020-2028) ($MN)
• Table 86 South America Cancer Registry Software Market Outlook, By Type (2020-2028) ($MN)
• Table 87 South America Cancer Registry Software Market Outlook, By Standalone Software (2020-2028) ($MN)
• Table 88 South America Cancer Registry Software Market Outlook, By Integrated Software (2020-2028) ($MN)
• Table 89 South America Cancer Registry Software Market Outlook, By Database Type (2020-2028) ($MN)
• Table 90 South America Cancer Registry Software Market Outlook, By Public Database (2020-2028) ($MN)
• Table 91 South America Cancer Registry Software Market Outlook, By Commercial Database (2020-2028) ($MN)
• Table 92 South America Cancer Registry Software Market Outlook, By Functionality (2020-2028) ($MN)
• Table 93 South America Cancer Registry Software Market Outlook, By Product Outcome Evaluation (2020-2028) ($MN)
• Table 94 South America Cancer Registry Software Market Outlook, By Cancer Reporting to Meet State and Federal Regulations (2020-2028) ($MN)
• Table 95 South America Cancer Registry Software Market Outlook, By Medical Research & Clinical Studies (2020-2028) ($MN)
• Table 96 South America Cancer Registry Software Market Outlook, By Patient Care Management (2020-2028) ($MN)
• Table 97 South America Cancer Registry Software Market Outlook, By Deployment Model (2020-2028) ($MN)
• Table 98 South America Cancer Registry Software Market Outlook, By Cloud-based (2020-2028) ($MN)
• Table 99 South America Cancer Registry Software Market Outlook, By On-premise (2020-2028) ($MN)
• Table 100 South America Cancer Registry Software Market Outlook, By End User (2020-2028) ($MN)
• Table 101 South America Cancer Registry Software Market Outlook, By Research Centre (2020-2028) ($MN)
• Table 102 South America Cancer Registry Software Market Outlook, By Hospitals & Medical Practices (2020-2028) ($MN)
• Table 103 South America Cancer Registry Software Market Outlook, By Private Payers (2020-2028) ($MN)
• Table 104 South America Cancer Registry Software Market Outlook, By Pharmaceutical, Biotechnology, and Medical Device Companies (2020-2028) ($MN)
• Table 105 South America Cancer Registry Software Market Outlook, By Government Organizations & Third-Party Administrators (2020-2028) ($MN)
• Table 106 Middle East & Africa Cancer Registry Software Market Outlook, By Country (2020-2028) ($MN)
• Table 107 Middle East & Africa Cancer Registry Software Market Outlook, By Type (2020-2028) ($MN)
• Table 108 Middle East & Africa Cancer Registry Software Market Outlook, By Standalone Software (2020-2028) ($MN)
• Table 109 Middle East & Africa Cancer Registry Software Market Outlook, By Integrated Software (2020-2028) ($MN)
• Table 110 Middle East & Africa Cancer Registry Software Market Outlook, By Database Type (2020-2028) ($MN)
• Table 111 Middle East & Africa Cancer Registry Software Market Outlook, By Public Database (2020-2028) ($MN)
• Table 112 Middle East & Africa Cancer Registry Software Market Outlook, By Commercial Database (2020-2028) ($MN)
• Table 113 Middle East & Africa Cancer Registry Software Market Outlook, By Functionality (2020-2028) ($MN)
• Table 114 Middle East & Africa Cancer Registry Software Market Outlook, By Product Outcome Evaluation (2020-2028) ($MN)
• Table 115 Middle East & Africa Cancer Registry Software Market Outlook, By Cancer Reporting to Meet State and Federal Regulations (2020-2028) ($MN)
• Table 116 Middle East & Africa Cancer Registry Software Market Outlook, By Medical Research & Clinical Studies (2020-2028) ($MN)
• Table 117 Middle East & Africa Cancer Registry Software Market Outlook, By Patient Care Management (2020-2028) ($MN)
• Table 118 Middle East & Africa Cancer Registry Software Market Outlook, By Deployment Model (2020-2028) ($MN)
• Table 119 Middle East & Africa Cancer Registry Software Market Outlook, By Cloud-based (2020-2028) ($MN)
• Table 120 Middle East & Africa Cancer Registry Software Market Outlook, By On-premise (2020-2028) ($MN)
• Table 121 Middle East & Africa Cancer Registry Software Market Outlook, By End User (2020-2028) ($MN)
• Table 122 Middle East & Africa Cancer Registry Software Market Outlook, By Research Centre (2020-2028) ($MN)
• Table 123 Middle East & Africa Cancer Registry Software Market Outlook, By Hospitals & Medical Practices (2020-2028) ($MN)
• Table 124 Middle East & Africa Cancer Registry Software Market Outlook, By Private Payers (2020-2028) ($MN)
• Table 125 Middle East & Africa Cancer Registry Software Market Outlook, By Pharmaceutical, Biotechnology, and Medical Device Companies (2020-2028) ($MN)
• Table 126 Middle East & Africa Cancer Registry Software Market Outlook, By Government Organizations & Third-Party Administrators (2020-2028) ($MN)